Squamous cell carcinoma of head and neck
Clinical trials for Squamous cell carcinoma of head and neck explained in plain language.
Never miss a new study
Get alerted when new Squamous cell carcinoma of head and neck trials appear
Sign up with your email to follow new studies for Squamous cell carcinoma of head and neck, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could less chemo be enough? new trial tests shorter treatment for head and neck cancer
Disease control OngoingThis phase 2 trial is testing whether giving only 4 cycles of chemotherapy alongside the immunotherapy drug pembrolizumab can effectively treat PD-L1-positive head and neck cancer that has spread or come back. Standard treatment usually involves 6 cycles of chemo. The study will …
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug duo aims to shrink tough head and neck tumors
Disease control OngoingThis study tests a new combination of two drugs (SI-B001 and SI-B003) with or without chemotherapy in people with advanced head and neck cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the treatment can shrink tumors. About 130 adults a…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1/2 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could fewer radiation sessions after surgery improve quality of life for head and neck cancer patients?
Disease control OngoingThis study tests a shorter, more intense course of radiation therapy (hypofractionated IMRT) given after surgery for head and neck cancer. The goal is to see if it is safe and if it can help patients maintain better swallowing function compared to the standard longer radiation sc…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1/2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Custom-Made vaccine takes on tough cancers in early trial
Disease control PausedThis early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo aims to improve head and neck cancer outcomes
Disease control OngoingThis study tests whether adding two drugs, pembrolizumab and olaparib, before and after standard chemoradiation can help control locally advanced head and neck cancer. About 45 adults with this cancer will receive the drug combination. The main goal is to see if this approach imp…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New personalized vaccine aims to keep head and neck cancer from returning
Disease control OngoingThis study tests a new personalized immunotherapy called TG4050 for people with advanced head and neck cancer. The treatment is designed to train the immune system to recognize and attack each patient's unique tumor mutations. The goal is to see if it is safe and can help prevent…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1/2 • Sponsor: Transgene • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Cancer drug trial pulled before it even started
Disease control CancelledThis study aimed to see if the drug TTI-101 could slow tumor growth in people with HPV-negative head and neck cancer before they had surgery. It was designed for patients with stage II to IV cancer that could be removed. However, the trial was withdrawn before enrolling any parti…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New combo therapy aims to boost immune attack on hard-to-treat cancers
Disease control OngoingThis early-phase study tests a new drug called NBTXR3, which is injected into tumors and activated by radiation. It is combined with an immunotherapy (anti-PD-1) to see if it can help the immune system fight advanced cancers better. The study involves about 145 people with variou…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1 • Sponsor: Nanobiotix • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New Immune-Boosting drug takes on tough cancers in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called AB248, which aims to boost the body's cancer-fighting immune cells. It is given alone or with the approved immunotherapy Keytruda to adults with advanced solid tumors like lung cancer, melanoma, or kidney cancer. The main g…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Phase 1 • Sponsor: Asher Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 26, 2026 15:50 UTC
-
Saliva test for head and neck cancer? new study explores microRNA clues
Knowledge-focused OngoingThis study collects saliva, blood, and tissue samples from 225 people with and without head and neck cancer. Researchers look for tiny genetic markers called microRNAs that might help diagnose the disease or predict how it will progress. The goal is to develop a simple, non-invas…
Matched conditions: SQUAMOUS CELL CARCINOMA OF HEAD AND NECK
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC